Signatur Biosciences

Emerging

Company Overview

Signatur Biosciences develops simple PCR-based diagnostic tests that detect complex diseases like breast cancer using standard qPCR machines, making sophisticated testing as accessible as COVID tests. Founded in 2022 and backed by Y Combinator (S22), the London-based company raised $7M in May 2025 to scale its affordable, point-of-care diagnostic solutions. Their smart PCR kits enable fast, local testing on existing laboratory equipment, addressing critical accessibility challenges in healthcare diagnostics.

Revenue
$7M
Loading News...
Loading Timeline...
Loading Culture...
Loading Leadership...

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Emerging Innovator

Signatur Biosciences is an emerging player bringing innovative solutions to the Healthcare market.

Frequently Asked Questions

AI Visibility Rankings

How Signatur Biosciences performs in AI search results

AI Rank
?
Track your position
Platforms
5
ChatGPT, Gemini, Claude...
Visibility
?
Your mention rate
Premium Feature

Unlock AI Visibility Tracking for Signatur Biosciences

See exactly how Signatur Biosciences ranks across ChatGPT, Gemini, Perplexity, Claude, and Grok. Get actionable insights to improve your AI search performance.

Real-time Rankings
Track your position daily
Competitive Intel
See how you compare
Platform Breakdown
Per-AI performance
Actionable Insights
Optimize your visibility
Start Tracking for Free

Join 1,000+ brands · Free 7-day trial · No credit card required

Want to improve your AI visibility? Track performance across all major AI platforms.
Compare with Other Brands

Compare with Other Brands

See how Signatur Biosciences stacks up against competitors with our detailed comparison tool.

Start Comparison